| 摘要 |
FIELD: medicine. ^ SUBSTANCE: invention refers to a method of treating ocular neovascularisation, angiogenesis, retinal hypostasis, diabetic retinopathy, and/or retinal ischemia to prevent visual acuity loss associated with such conditions. The invention provides introduction to a patient requiring of a composition containing therapeutically effective amount of receptor tyrosine kinase inhibitor that blocks tyrosine auto-phosphorylation of 2 VEGF receptor with IC50 less than 10 nM and of at least one receptor chosen from the group including receptor 1 VEGF, receptor 3 VEGF, Tie-2, PDGFR, c-KIT, Flt-3 and CSF-IR with IC50 less than 100 nM. ^ EFFECT: method allows preventing visual acuity loss associated with eye neovascularisation, angiogenesis, retinal hypostasis, diabetic retinopathy, and/or retinal ischemia. ^ 17 cl, 5 tbl, 9 dwg, 8 ex |
